Stryker recently reported strong quarterly results, especially in hips and knees. But, as one analyst pointed out during the company’s earnings call, investors may be skeptical about the sustainability of that growth.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,